相关实验视频

Updated: Jun 26, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

装有MSC微小的G-四重复增强圆形单链DNA-9通过向MDSCs来抑制瘤生长

Jingxia Han¹, Rong Qin¹, Shaoting Zheng¹

¹State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.

Journal of nanobiotechnology

|May 12, 2024

概括

研究人员开发了一种新型DNA药物 (G4-CSSD9),通过微囊传递,以向和抑制免疫抑制性髓质衍生抑制细胞 (MDSC),为黑色素瘤治疗提供了一种新策略.

科学领域:

生物技术是生物技术.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

骨髓原抑制细胞 (MDSCs) 是瘤进展和免疫疗法耐药性的关键驱动因素.
在MDSCs中的微RNA (miRNA) 促成了它们的免疫抑制功能.
在MDSC中通过微囊传递准miRNA为恶性瘤提供了治疗机会.

研究的目的:

设计和开发一种新的核酸药物,用于针对MDSC中的miRNA.
为了研究微微囊封药物输送用于癌症治疗的疗效.
为了减少MDSCs在黑色素瘤治疗中的免疫抑制功能.

主要方法:

用G-四重复增强的圆形单链DNA-9 (G4-CSSD9) 的设计,专门结合miR-9.
通过膜挤出制备介质干细胞 (MSC) 微 (MVs).
将G4-CSSD9封装在MSC微微囊中 (MVs@G4-CSSD9) 以有针对性地传递给MDSC.

主要成果:

G4-CSSD9表现出miR-9序列的特定吸附,并且由于其G-四重复结构,表现出良好的稳定性.
MVs@G4-CSSD9有效地将治疗DNA传递到MDSC中.
用MVs@G4-CSSD9治疗通过影响下游转录和翻译,降低了MDSCs的免疫抑制功能.

结论:

开发的MVs@G4-CSSD9系统成功降低了MDSC免疫抑制,显示了黑色素瘤治疗的潜力.
这项研究提供了一种新的策略,用于利用工程DNA和微微来向癌症治疗中的MDSC.
这些发现通过调节瘤微环境,为恶性瘤治疗提供了有希望的方法.

关键词:

G-四重复增强的圆形单链DNA-9 黑色素瘤是一种黑色素瘤.来自骨髓细胞的抑制细胞.带介质干细胞是带介质干细胞.在 miR-9 系统中,

更多相关视频

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...